Aevius, a Mass General Brigham spinout, launched on November 17 with $22 million in funding led by Insight Partners for AI designed to reuse a patient’s medical history across clinical and research tasks.

The Boston startup is targeting health systems, insurers and drugmakers. Its models combine medical records, imaging and other clinical data into a patient profile that changes as new information arrives, according to the company.

Aevius says organizations could build several applications on that shared profile. A drugmaker could use it to study how a disease progresses or find candidates for clinical studies, without assembling the patient’s history again for each new question.

Aevius plans to use the financing for commercial deployment, further model and product development, and new engineering, clinical and commercial hires. Physician-scientist Rowland Pettit leads the company as chief executive, with Ming Yang (Max) Lu as chief technology officer.

Pettit, Lu and fellow co-founders Faisal Mahmood and Long Phi Le were part of Modella AI’s founding team. AstraZeneca’s February 10 results disclosure says it acquired Modella in the fourth quarter of 2025 and planned to bring its models and AI agents into oncology research and development.

Sources
1Aevius financing announcement via BioSpace ↗
2Aevius company overview and team ↗
3AstraZeneca FY and Q4 2025 results ↗